114 related articles for article (PubMed ID: 30267148)
21. Statins do not inhibit the FGFR signaling in chondrocytes.
Fafilek B; Hampl M; Ricankova N; Vesela I; Balek L; Kunova Bosakova M; Gudernova I; Varecha M; Buchtova M; Krejci P
Osteoarthritis Cartilage; 2017 Sep; 25(9):1522-1530. PubMed ID: 28583899
[TBL] [Abstract][Full Text] [Related]
22. In situ imaging of quantum dot-AZD4547 conjugates for tracking the dynamic behavior of fibroblast growth factor receptor 3.
Hwang G; Kim H; Yoon H; Song C; Lim DK; Sim T; Lee J
Int J Nanomedicine; 2017; 12():5345-5357. PubMed ID: 28794627
[TBL] [Abstract][Full Text] [Related]
23. Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.
Sethakorn N; O'Donnell PH
BJU Int; 2016 Nov; 118(5):681-691. PubMed ID: 27271022
[TBL] [Abstract][Full Text] [Related]
24. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas.
Lehtinen B; Raita A; Kesseli J; Annala M; Nordfors K; Yli-Harja O; Zhang W; Visakorpi T; Nykter M; Haapasalo H; Granberg KJ
BMC Cancer; 2017 May; 17(1):310. PubMed ID: 28468611
[TBL] [Abstract][Full Text] [Related]
25. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
[TBL] [Abstract][Full Text] [Related]
26. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
27. Expression of FGFR3 during human testis development and in germ cell-derived tumours of young adults.
Ewen KA; Olesen IA; Winge SB; Nielsen AR; Nielsen JE; Graem N; Juul A; Rajpert-De Meyts E
Int J Dev Biol; 2013; 57(2-4):141-51. PubMed ID: 23784824
[TBL] [Abstract][Full Text] [Related]
28. A place for precision medicine in bladder cancer: targeting the FGFRs.
di Martino E; Tomlinson DC; Williams SV; Knowles MA
Future Oncol; 2016 Oct; 12(19):2243-63. PubMed ID: 27381494
[TBL] [Abstract][Full Text] [Related]
29. FGFR-targeted therapeutics for the treatment of breast cancer.
De Luca A; Frezzetti D; Gallo M; Normanno N
Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast surface-associated FGF-2 promotes contact-dependent colorectal cancer cell migration and invasion through FGFR-SRC signaling and integrin αvβ5-mediated adhesion.
Knuchel S; Anderle P; Werfelli P; Diamantis E; Rüegg C
Oncotarget; 2015 Jun; 6(16):14300-17. PubMed ID: 25973543
[TBL] [Abstract][Full Text] [Related]
31. Generation of monoclonal antibody targeting fibroblast growth factor receptor 3.
Gorbenko O; Ovcharenko G; Klymenko T; Zhyvoloup O; Gaman N; Volkova D; Gout I; Filonenko V
Hybridoma (Larchmt); 2009 Aug; 28(4):295-300. PubMed ID: 19663703
[TBL] [Abstract][Full Text] [Related]
32. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
33. Ablation of Perlecan Domain 1 Heparan Sulfate Reduces Progressive Cartilage Degradation, Synovitis, and Osteophyte Size in a Preclinical Model of Posttraumatic Osteoarthritis.
Shu CC; Jackson MT; Smith MM; Smith SM; Penm S; Lord MS; Whitelock JM; Little CB; Melrose J
Arthritis Rheumatol; 2016 Apr; 68(4):868-79. PubMed ID: 26636652
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
von Mässenhausen A; Deng M; Billig H; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Göke F; Franzen A; Heasley L; Kirfel J; Brägelmann J; Perner S
Target Oncol; 2016 Oct; 11(5):631-642. PubMed ID: 27053219
[TBL] [Abstract][Full Text] [Related]
35. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling.
Ben-Zvi T; Yayon A; Gertler A; Monsonego-Ornan E
J Cell Sci; 2006 Jan; 119(Pt 2):380-7. PubMed ID: 16410555
[TBL] [Abstract][Full Text] [Related]
36. FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients.
Wang Z; Zhang C; Sun L; Liang J; Liu X; Li G; Yao K; Zhang W; Jiang T
Oncotarget; 2016 Dec; 7(51):84587-84593. PubMed ID: 27829236
[TBL] [Abstract][Full Text] [Related]
37. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
38. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
39. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
40. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
